|Bid||65.01 x 100|
|Ask||65.85 x 100|
|Day's Range||65.43 - 66.26|
|52 Week Range||55.06 - 68.12|
|PE Ratio (TTM)||17.07|
|Dividend & Yield||2.56 (3.91%)|
|1y Target Est||N/A|
AbbVie expects its biggest drug, Humira, to hit peak international sales in 2018 and then face erosion as cheaper biosimilars enter the market.
Regeneron and Sanofi's rheumatoid arthritis drug is 15%-30% cheaper than rival drugs from Amgen, AbbVie and Roche, an analyst said Tuesday.